All News
Benefits in Myasthenia Gravis Extend to 52 Weeks With Inebilizumab
(MedPage Today) -- SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine recep
Read MoreHospitals in England to get unlimited ‘incentive payments’ for patients taken off waiting lists
Exclusive: NHS trusts told to review every person on list amid warnings about long waits in A&E and for cancer careHospitals in England will receive unlimited “incentive payments” to remove pe
Read MoreTell us: what have you never quite understood about weight loss drugs?
Perhaps you’ve tried them, are thinking about it, or feel overwhelmed by the hype.
Read MoreDoc 'Snapped' Before Killing Wife; Ob/Gyn's Defamation Case; Doc Accused of Peeping
(MedPage Today) -- "I snapped." Massachusetts urologist Ingolf Tuerk, MD, wept during his murder trial as he described killing his wife.
Read MoreThe Hope of the DO Initials
(MedPage Today) -- In his recent MedPage Today op-ed, "The Magic of the MD Initials," Neil Baum, MD, raises a timely and important question: How can physicians rebuild the trust of a public awash in
Read MoreHave you seen examples of health care fraud, waste or abuse? Tell us about it.
New York Times reporters are looking into cases of unnecessary and wasteful spending in government health programs.
Read MoreSTAT+: Pharmalittle: We’re reading about the FDA closing generic drug office, its U-turn on remote work, and more
A FDA generic drug office was eliminated — and the implications will be felt not only by drugmakers, but consumers
Read MorePublic Health Org Calls for RFK Jr. to 'Resign or Be Fired'
(MedPage Today) -- HHS Secretary Robert F. Kennedy Jr.
Read MoreTrump's Physical Exam; RFK Jr. Endorses Measles Shot; Vax Refuseniks Rejoin Military
(MedPage Today) -- Note that some links may require registration or subscription. MedPage Today is collecting stories of HHS staffers across all agencies affected by Trump administration cuts.
Read MoreSTAT+: Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug
A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences may need to issue compulsory licenses.
Read More